Accelerate digital transformation by leveraging advanced technologies, optimizing operational efficiency, enhancing productivity, and improving customer experience, while fostering a seamlessly connected partner ecosystem.
Maximize the capacity of 12 EU-GMP production lines through process optimization and investment in modern operational systems to meet both domestic and international market demands.
Enhance workforce productivity by standardizing processes, providing specialized training, and equipping medical representatives with digital tools. Post-restructuring, resources will be strategically allocated to sharpen competitive advantage.
Accelerate R&D investment, targeting the launch of 20 new products annually, with a focus on expanding the EU Visa-certified portfolio and advancing biosimilars and biologics.
Strengthen strategic technology partnerships to enhance manufacturing capabilities, optimize production efficiency, and expand the portfolio of high-value pharmaceutical products.
Execute Cat Khanh Pharmaceutical Complex project, slated for commercial operations by 2028.
Expand export markets, prioritizing Southeast Asia, North Asia, the Middle East, Africa, and Europe, to drive revenue growth and establish Imexpharm as a global pharmaceutical leader.
